Tanezumab

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameTanezumab
Drug Alias Nametanezumab他尼珠单抗他奈珠单抗tanezumabumPF-04383119 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta-nerve growth factor inhibitors
TargetsBeta-nerve growth factor
Therapy Area/IndicationsBone metastasesDiabetic peripheral neuropathyChronic Pain +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncEli Lilly And Company
Inactive CompaniesPfizer Manufacturing Belgium NvHui Zhi Pharmaceutical (Dalian) Co Ltd
Active IndicationsBone metastasesCancer PainNeurilemmoma
Inactive IndicationsDiabetic peripheral neuropathyChronic PainLow Back Pain +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG